Prospective Regional Epilepsy Database
Launched by SAHLGRENSKA UNIVERSITY HOSPITAL · Sep 16, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Prospective Regional Epilepsy Database (PREDICT) is a study designed to learn more about epilepsy, a condition that causes seizures. Researchers in western Sweden are following adults who have experienced an unprovoked seizure (a seizure that happens without any clear cause) or have been diagnosed with epilepsy. The goal is to find out more about the genetic factors and other markers that could help with the diagnosis and treatment of epilepsy, as well as to understand the long-term effects of living with this condition.
To participate in this study, individuals need to be over 18 years old and have had an unprovoked seizure in the last year or a diagnosis of epilepsy within certain guidelines. Unfortunately, people who are expected to live for less than two more years or cannot provide informed consent (which means they can’t fully understand the study details) are not eligible. Participants will have the chance to contribute to important research that could help improve future treatments for epilepsy, and they will be closely monitored by healthcare professionals throughout the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Over 18 years of age
- • An unprovoked seizure within the last year or a diagnosis of epilepsy according to the current International League Against Epilepsy definition (epilepsy with seizure in the last ten or antiepileptic drug treatment in the last five years)
- Exclusion Criteria:
- • Expected survival less than two years
- • Inability to give informed consent
About Sahlgrenska University Hospital
Sahlgrenska University Hospital, a leading healthcare institution in Sweden, is at the forefront of clinical research and innovation. Affiliated with the University of Gothenburg, the hospital integrates advanced medical care with cutting-edge research, facilitating a collaborative environment for scientific exploration and clinical trials. With a commitment to improving patient outcomes, Sahlgrenska University Hospital focuses on a wide range of therapeutic areas, leveraging its multidisciplinary expertise to advance healthcare solutions. The institution is dedicated to fostering ethical research practices and ensuring the highest standards of patient safety and care in all clinical trials.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gothenburg, , Sweden
Borås, , Sweden
Gothenburg, , Sweden
Patients applied
Trial Officials
Johan Zelano, MD PhD
Principal Investigator
Sahlgrenska University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials